Nuvectis Pharma Stock Performance
| NVCT Stock | USD 8.76 0.04 0.45% |
On a scale of 0 to 100, Nuvectis Pharma holds a performance score of 14. The company secures a Beta (Market Risk) of 1.29, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nuvectis Pharma will likely underperform. Please check Nuvectis Pharma's downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Nuvectis Pharma's current price movements will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nuvectis Pharma are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Nuvectis Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.45) | Five Day Return 2.22 | Year To Date Return 2.94 | Ten Year Return 169.54 | All Time Return 169.54 |
1 | Buy Rating for Nuvectis Pharmas NXP900 Driven by Promising Efficacy and Development Progress - TipRanks | 11/18/2025 |
2 | Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osi... | 11/25/2025 |
3 | Acquisition by Mosseri Marlio Charles of 5394 shares of Nuvectis Pharma at 14.4 subject to Rule 16b-3 | 12/03/2025 |
4 | Nuvectis Pharma, Inc.s market cap rose US18m last week individual investors who hold 44 percent profited and so did insiders | 12/05/2025 |
5 | Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC | 12/17/2025 |
6 | Acquisition by Carson Michael J. of 61200 shares of Nuvectis Pharma subject to Rule 16b-3 | 01/06/2026 |
7 | Movement as an Input in Quant Signal Sets - Stock Traders Daily | 01/28/2026 |
8 | Analysts Offer Insights on Healthcare Companies Nuvectis Pharma , Tenet Healthcare and Upstream Bio, Inc. - The Globe and Mail | 02/13/2026 |
Nuvectis Pharma Relative Risk vs. Return Landscape
If you would invest 608.00 in Nuvectis Pharma on November 16, 2025 and sell it today you would earn a total of 268.00 from holding Nuvectis Pharma or generate 44.08% return on investment over 90 days. Nuvectis Pharma is currently generating 0.6655% in daily expected returns and assumes 3.6758% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Nuvectis, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nuvectis Pharma Target Price Odds to finish over Current Price
The tendency of Nuvectis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.76 | 90 days | 8.76 | about 13.69 |
Based on a normal probability distribution, the odds of Nuvectis Pharma to move above the current price in 90 days from now is about 13.69 (This Nuvectis Pharma probability density function shows the probability of Nuvectis Stock to fall within a particular range of prices over 90 days) .
Nuvectis Pharma Price Density |
| Price |
Predictive Modules for Nuvectis Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nuvectis Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nuvectis Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nuvectis Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nuvectis Pharma is not an exception. The market had few large corrections towards the Nuvectis Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nuvectis Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nuvectis Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.53 | |
β | Beta against Dow Jones | 1.29 | |
σ | Overall volatility | 1.06 | |
Ir | Information ratio | 0.15 |
Nuvectis Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nuvectis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nuvectis Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nuvectis Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (26.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvectis Pharma currently holds about 13.57 M in cash with (16.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Nuvectis Pharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 42.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies Nuvectis Pharma , Tenet Healthcare and Upstream Bio, Inc. - The Globe and Mail |
Nuvectis Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nuvectis Stock often depends not only on the future outlook of the current and potential Nuvectis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nuvectis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21.8 M | |
| Cash And Short Term Investments | 31.6 M |
Nuvectis Pharma Fundamentals Growth
Nuvectis Stock prices reflect investors' perceptions of the future prospects and financial health of Nuvectis Pharma, and Nuvectis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nuvectis Stock performance.
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 197.68 M | ||||
| Shares Outstanding | 26.49 M | ||||
| Price To Book | 9.71 X | ||||
| EBITDA | (19 M) | ||||
| Net Income | (26.44 M) | ||||
| Cash And Equivalents | 13.57 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 13.3 M | ||||
| Current Ratio | 5.20 X | ||||
| Book Value Per Share | 0.72 X | ||||
| Cash Flow From Operations | (16.01 M) | ||||
| Earnings Per Share | (1.37) X | ||||
| Market Capitalization | 233.13 M | ||||
| Total Asset | 31.71 M | ||||
| Retained Earnings | (99.69 M) | ||||
| Working Capital | 9.71 M | ||||
About Nuvectis Pharma Performance
Assessing Nuvectis Pharma's fundamental ratios provides investors with valuable insights into Nuvectis Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nuvectis Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.91) | (0.96) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (1.57) | (1.65) |
Things to note about Nuvectis Pharma performance evaluation
Checking the ongoing alerts about Nuvectis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nuvectis Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nuvectis Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (26.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvectis Pharma currently holds about 13.57 M in cash with (16.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Nuvectis Pharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 42.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies Nuvectis Pharma , Tenet Healthcare and Upstream Bio, Inc. - The Globe and Mail |
- Analyzing Nuvectis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nuvectis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Nuvectis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nuvectis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nuvectis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nuvectis Pharma's stock. These opinions can provide insight into Nuvectis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.